The ProLung Test evaluates the likelihood that a patient has a malignant lung mass, and does so immediately, non-invasively, and with a high degree of accuracy. The test can facilitate the early diagnosis and effective treatment of lung cancer and thereby help reduce the high mortality rate of this deadly disease.

•	Today, lung cancer is the deadliest of all cancers killing 1.4 million people world-wide. That's more than breast, prostate, colon and melanoma cancers combined
•	A core problem has been the inability to safely identify a malignancy in the lung early enough for treatment to be effective.
•	In a study at Johns Hopkins University School of Medicine, the ProLung Test instantly distinguished malignant from benign lung masses with 90% accuracy, through non-invasive bioconductance measurements.
•	The ProLung Test offers shareholders the opportunity to help those at high risk for lung cancer while obtaining a superior return.

 

To learn more, click here to watch the video.